When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the skin may be just as effective as traditional means of administration with ...

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

In recognition, the NFLPA will donate $100,000 to Slayton’s Left-Hand Right-Hand (LHRH) Foundation. “Winning this award means more than words can describe,” Slayton said. “The main goal ...

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...